Divarasib Versus Adagrasib or Sotorasib in Pretreated KRAS G12C+Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Gadgeel, S. [1 ]
Rahman, A. [2 ]
Osaghae, U. [3 ]
Fernando, T. M. [3 ]
Lin, M. T. [3 ]
Koli, K. [3 ]
Meyenberg, C. [4 ]
Mathisen, M. [3 ]
Skoulidis, F. [5 ]
机构：
[1] Henry Ford Hlth, Henry Ford Canc Inst, Detroit, MI USA
[2] F Hoffmann La Roche Ltd, Welwyn Garden City, Herts, England
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.12D.07
引用
收藏
页码：S349 / S349
页数：1
相关论文
共 50 条
  • [21] KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non-Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
    Janne, P. A.
    Rybkin, I. I.
    Spira, A. I.
    Riely, G. J.
    Papadopoulos, K. P.
    Sabari, J. K.
    Johnson, M. L.
    Heist, R. S.
    Bazhenova, L.
    Barve, M.
    Pacheco, J. M.
    Leal, T. A.
    Velastegui, K.
    Cornelius, C.
    Olson, P.
    Christensen, J. G.
    Kheoh, T.
    Chao, R. C.
    Ou, S. H. I.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S1 - S2
  • [22] Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT)
    Dingemans, Anne-Marie C.
    Syrigos, Konstantinos
    Livi, Lorenzo
    Paulus, Astrid
    Kim, Sang-We
    Chen, Yuanbin
    Felip, Enriqueta
    Griesinger, Frank
    Ohashi, Kadoaki
    Zalcman, Gerard
    Hughes, Brett Gordon Maxwell
    Sorensen, Jens Benn
    Blais, Normand
    Ferreira, Carlos G. M.
    Lindsay, Colin R.
    Dziadziuszko, Rafal
    Ward, Patrick J.
    Obiozor, Cynthia Chinedu
    Wang, Yang
    Peters, Solange
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [23] Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program (EAP)
    Awad, M.
    Pelizzari, G.
    Stevenson, J. P.
    Majem Tarruella, M.
    Ferreira, C. G. M.
    Petty, W. J.
    Arriola, E.
    de Castro, J.
    Morbeck, I.
    Bauman, J. R.
    Toschi, L.
    Zer, A.
    Metro, G.
    Kalmadi, S.
    Azkarate Martinez, A.
    Xia, C.
    Meloni, A.
    Obiozor, C.
    Maimon, N.
    Novello, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1005 - S1005
  • [24] Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital
    Bessy, C.
    Blin, T.
    Pichon, E.
    Marchand-Adam, S.
    Carmier, D.
    REVUE DES MALADIES RESPIRATOIRES, 2023, 40 (01) : 17 - 23
  • [25] KRAS G12C mutations in non-small cell lung cancer
    Li, J. J.
    Wu, X. J.
    Farzin, M.
    Bray, V.
    Williamson, J.
    Pal, A.
    Yip, P. Y.
    Hagelamin, A.
    Ding, P.
    Nindra, U.
    Vinod, S.
    French, B.
    Chua, W.
    Gupta, R.
    Cooper, W. A.
    Wang, B.
    Lee, C. S.
    HISTOPATHOLOGY, 2024, 85 : 25 - 25
  • [26] Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
    Girard, N.
    Perol, M.
    Debieuvre, D.
    Bosquet, L.
    Veillard, C.
    Caillon, M.
    Tzala, L.
    Desamericq, G.
    Valette, C. Audigier
    ANNALS OF ONCOLOGY, 2023, 34
  • [27] Early changes in circulating cell free KRAS G12C as a possible blood-based response biomarker for adagrasib in non-small cell lung cancer (NSCLC)
    Paweletz, Cloud
    Heavey, Grace A.
    Kuang, Yanan
    Kheoh, Thian
    Anderes, Kenna
    Christensen, James
    Janne, Pasi A.
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [28] CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
    Reck, M.
    Spira, A.
    Besse, B.
    Wolf, J.
    Skoulidis, F.
    Borghaei, H.
    Goto, K.
    Park, K.
    Griesinger, F.
    Felip, E.
    Boyer, M.
    Barrios, C. H.
    Goss, G.
    Yang, H.
    Obiozor, C.
    Ramalingam, S. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S894 - S895
  • [29] Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients
    Paweletz, Cloud P.
    Heavey, Grace A.
    Kuang, Yanan
    Durlacher, Emily
    Kheoh, Thian
    Chao, Richard C.
    Spira, Alexander I.
    Leventakos, Konstantinos
    Johnson, Melissa L.
    Ou, Sai-Hong Ignatius
    Riely, Gregory J.
    Anderes, Kenna
    Yang, Wenjing
    Christensen, James G.
    Janne, Pasi A.
    CLINICAL CANCER RESEARCH, 2023, 29 (16) : 3074 - 3080
  • [30] Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer
    Skoulidis, Ferdinandos
    Li, Bob T.
    Hochmair, Maximilian
    Govindan, Ramaswamy
    Vincent, Mark
    van der Wekken, Anthonie J.
    Reguart Aransay, Noemi
    O'Byrne, Kenneth J.
    Girard, Nicolas
    Griesinger, Frank
    Nishio, Makoto
    Haefliger, Simon
    Lindsay, Colin
    Reinmuth, Niels
    Paulus, Astrid
    Papakotoulas, Pavlos
    Kim, Sang-We
    Ferreira, Carlos Gil
    Pasello, Giulia
    Duruisseaux, Michael
    Gennatas, Spyridon
    Dimou, Anastasios
    Mehta, Bhakti
    Kormany, William
    Nduka, Chidozie
    Sylvester, Brooke E.
    Ardito-Abraham, Christine
    Wang, Yang
    de Langen, Adrianus Johannes
    ONCOLOGIST, 2025, 30 (01):
12345